Parkman Healthcare Partners’s ResMed RMD Stock Holding History

Parkman Healthcare Partners’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-22,622	Closed	-$5.06M	–	100
2025 Q1	$5.06M	Buy	+22,622	New	+$5.28M	0.6%	49

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Parkman Healthcare Partners's RMD Position: Q2 2025 in Review

Parkman Healthcare Partners sold out of ResMed (RMD) in Q2 2025, closing a stake of 22,622 shares — an estimated $5.06M sold.

Parkman Healthcare Partners first reported a position in RMD in Q1 2025 and held it in 1 quarter. The position peaked at $5.06M in Q1 2025. 920 funds tracked by Wall St. Rank hold RMD as of Q2 2025.

Parkman Healthcare Partners reported no remaining ResMed position as of Q2 2025 after selling out during the quarter.
Parkman Healthcare Partners sold 22,622 ResMed shares in Q2 2025, an estimated $5.06M.
Parkman Healthcare Partners first reported a position in ResMed in Q1 2025 and held it in 1 quarter.
Parkman Healthcare Partners's ResMed position peaked at $5.06M in Q1 2025.
920 funds tracked by Wall St. Rank held ResMed as of Q2 2025.

Based on Parkman Healthcare Partners's 13F filing for Q2 2025, filed 14 Aug 2025.